Abstract
Cellular senescence is a response to nonlethal intrinsic or extrinsic stress that results in persistent growth arrest with a distinct morphological and biochemical phenotype. The engagement of senescence may represent a key component for therapeutic intervention in the eradication of cancer. Nevertheless, for many years, the role of senescence in opposing tumour growth in vivo had previously been underestimated. The potential role of cellular senescence in anti-cancer therapy may be particularly attractive in advanced age, because of the age-related changes occurring at the level of both tumor suppressor genes and immune functions. This review, which is focused on the impact of cellular senescence in aging and cancer, summarises the intrinsic pathways and the molecular and epigenetic changes involved in the induction of cellular senescence, and analyzes the changes occurring at the level of these pathways during aging and cancer.
Keywords: Cellular senescence, cancer, aging, extrinsic stress, growth arrest, tumour growth, age-related changes, tumor suppressor genes, epigenetic changes, immune functions
Current Pharmaceutical Design
Title:Impact of Cellular Senescence in Aging and Cancer
Volume: 19 Issue: 9
Author(s): Mauro Provinciali, Maurizio Cardelli, Francesca Marchegiani and Elisa Pierpaoli
Affiliation:
Keywords: Cellular senescence, cancer, aging, extrinsic stress, growth arrest, tumour growth, age-related changes, tumor suppressor genes, epigenetic changes, immune functions
Abstract: Cellular senescence is a response to nonlethal intrinsic or extrinsic stress that results in persistent growth arrest with a distinct morphological and biochemical phenotype. The engagement of senescence may represent a key component for therapeutic intervention in the eradication of cancer. Nevertheless, for many years, the role of senescence in opposing tumour growth in vivo had previously been underestimated. The potential role of cellular senescence in anti-cancer therapy may be particularly attractive in advanced age, because of the age-related changes occurring at the level of both tumor suppressor genes and immune functions. This review, which is focused on the impact of cellular senescence in aging and cancer, summarises the intrinsic pathways and the molecular and epigenetic changes involved in the induction of cellular senescence, and analyzes the changes occurring at the level of these pathways during aging and cancer.
Export Options
About this article
Cite this article as:
Provinciali Mauro, Cardelli Maurizio, Marchegiani Francesca and Pierpaoli Elisa, Impact of Cellular Senescence in Aging and Cancer, Current Pharmaceutical Design 2013; 19 (9) . https://dx.doi.org/10.2174/1381612811319090017
DOI https://dx.doi.org/10.2174/1381612811319090017 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Methods of Preparation of Multifunctional Microbubbles and their In Vitro / In Vivo Assessment of Stability, Functional and Structural Properties
Current Pharmaceutical Design Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Marine Natural Products as a Promising Source of Therapeutic Compounds to Target Cancer Stem Cells
Current Medicinal Chemistry Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Research Highlights BAY 1436032: A Novel Pan-mutant IDH1 Inhibitor Extends Survival of Mice with Experimental Brain Tumors
CNS & Neurological Disorders - Drug Targets The Plasminogen Activation System Promotes Neurorepair in the Ischemic Brain
Current Drug Targets Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Trichostatin A - like Hydroxamate Histone Deacetylase Inhibitors as Therapeutic Agents: Toxicological Point of View
Current Medicinal Chemistry Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme
Current Molecular Pharmacology Adenovirus-mediated Transgene-engineered Dendritic Cell Vaccine of Cancer
Current Gene Therapy Continuous Nanostructures for the Controlled Release of Drugs
Current Pharmaceutical Design Alpha-Crystallins and Tumorigenesis
Current Molecular Medicine Glioma Dynamics and Computational Models: A Review of Segmentation, Registration, and In Silico Growth Algorithms and their Clinical Applications
Current Medical Imaging Unlocking the Benefits of Fasting: A Review of its Impact on Various Biological Systems and Human Health
Current Medicinal Chemistry Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Pharmacogenomics and Personalized Medicine